BC Week In Review | Mar 14, 2017
Clinical News

PKX-001: Ph I started

ProtoKinetix began an open-label, Canadian Phase I trial to evaluate transplanted islet cells treated with PKX-001 in up to 10 patients. ProtoKinetix Inc. (OTCQB:PKTX), St. Marys, W.Va.  Product: PKX-001 (AAGP)  Business: Endocrine/Metabolic  Molecular target: NA ...
BC Week In Review | Oct 17, 2011
Clinical News

ProtKinetix preclinical data

In rats, 0.2% topical AAGP penetrated the protective barriers of the eye and was detected within the cornea and ciliary body. There were no side effects associated with administration of the anti-inflammatory synthetic anti-aging glycopeptide...
Items per page:
1 - 2 of 2